Cancer risk communication, predictive testing and management in the United Kingdom, France, Germany and The Netherlands - An International Cancer Risk Communication Study (InCRisC)
Basic data for this project
Type of project: Participation in BMBF-joint project
Duration at the University of Münster: 01/07/2006 - 31/12/2010
Description
During the last 15 years predictive testing for common disorders such as breast cancer has moved from research into clinical practice. Currently in Western European countries predictive BRCA1/BRCA2 testing is offered using low, moderate and high risk based upon family history as cut-off levels. As predictive BRCA1/BRCA2 testing moves in to the mainstream of health care these tests are increasingly administered by physicians with no training in genetics.
Keywords: BRCA1/BRCA2; familial breast cancer; NICE guidelines; predictive genetic testing
Funding identifier: 01GP0617
Funder / funding scheme:
- Federal Ministry of Education and Research (BMBF)
Project management at the University of Münster
| Nippert, Irmgard | Institute of Human Genetics |
Applicants from the University of Münster
| Nippert, Irmgard | Institute of Human Genetics |
Project partners outside the University of Münster
- Genetic Alliance UKUnited Kingdom
- Leiden University Medical Center (LUMC)Netherlands (Kingdom of the)
- French Institute of Health and Medical Research (INSERM)France
- University of ManchesterUnited Kingdom
- St Mary’s Hospital, Department of Clinical GeneticsUnited Kingdom
- Hannover Medical School (MHH)Germany